Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants

• Main Authors: Megumi Inoue (Author), Tetsuro Ogawa (Author), Hiroshi Tamura (Author), Yosuke Hagiwara (Author), Yuki Saito (Author), Darren Abbanat (Author), Germie van den Dobbelsteen (Author), Peter Hermans (Author), Stefan Thoelen (Author), Jan Poolman (Author), Patricia Ibarra de Palacios (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This Phase 1, randomized, double-blind, placebo-controlled study was conducted to evaluate the safety, tolerability and immunogenicity of different doses of ExPEC4V conjugate vaccine (4-16µg Polysaccharide [PS]/serotype) in healthy Japanese participants, stratified into younger (≥20 to <50 years)...